Traws Pharma Files 2023 Annual Report Amendment

TL;DR

Traws Pharma (fka Onconova) filed its 2023 10-K amendment. Check for updates.

AI Summary

Traws Pharma, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2023. The company, formerly known as Onconova Therapeutics, Inc., is based in Newtown, PA, and operates in the pharmaceutical preparations sector. This amendment was filed on April 29, 2024.

Why It Matters

This filing provides updated information for the fiscal year 2023, which is crucial for investors to assess the company's financial health and strategic direction.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Traws Pharma is subject to inherent risks related to drug development, regulatory approvals, and market competition.

Key Players & Entities

• Traws Pharma, Inc. (company) — Filer of the 10-K/A
• Onconova Therapeutics, Inc. (company) — Former name of Traws Pharma, Inc.
• December 31, 2023 (date) — Fiscal year end
• April 29, 2024 (date) — Filing date of the amendment
• Newtown, PA (location) — Company address

FAQ

Filing Documents

• tm2412892d1_10ka.htm (10-K/A) — 459KB
• tm2412892d1_ex31-1.htm (EX-31.1) — 3KB
• tm2412892d1_ex31-2.htm (EX-31.2) — 3KB
• 0001104659-24-054006.txt ( ) — 725KB
• traw-20231231.xsd (EX-101.SCH) — 3KB
• traw-20231231_lab.xml (EX-101.LAB) — 36KB
• traw-20231231_pre.xml (EX-101.PRE) — 24KB
• tm2412892d1_10ka_htm.xml (XML) — 6KB

Executive Compensation

Executive Compensation 11 Item 12

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 19 Item 13 Certain Relationships and Related Transactions, and Director Independence 21 Item 14 Principal Accountant Fees and Services 22 PART IV Item 15 Exhibits and Financial Statement Schedules 23 i EXPLANATORY NOTE Traws Pharma Therapeutics, Inc., sometimes referred to as "we," "our," or the "Company" is filing this Amendment No. 1 on Form 10-K/A, or this Amendment, to its Annual Report on Form 10-K for the year ended December 31, 2023, originally filed on April 1, 2024, or the "Original Report," for the sole purpose of including the information required by Part III of Form 10-K. This information was previously omitted from the Original Report in reliance on General Instruction G(3) to Form 10-K, which permits the information in the above referenced items to be incorporated in the Form 10-K by reference from our definitive proxy statement if such statement is filed no later than 120 days after our fiscal year-end. We are filing this Amendment to provide information required in Part III of Form 10-K because a definitive proxy statement containing such information will not be filed by the Company within 120 days after the end of the fiscal year covered by the Form 10-K. In accordance with Rule 12b-15 under the Securities and Exchange Act of 1934, as amended, or the Exchange Act, Part III, Items 10 through 14 of the Original Report are hereby amended and restated in their entirety, and Part IV, Item 15 of the Original Report is hereby amended and restated in its entirety, with the only changes being the additions of the new certifications by our principal executive officer and principal financial officer filed herewith. This Amendment does not amend or otherwise update any other information in the Original Report. Accordingly, this Amendment should be read in conjunction with the Original Report and with our filings with the Securities and Exchange C

DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE. All of our directors bring to our Board of Directors executive leadership experience from their service as executives and/or directors of our Company and/or other entities. The biography of each of the nominees below contains information regarding the person's business experience, director positions held currently or at any time during the last five years, and the experiences, qualifications, attributes and skills that caused the Nominating and Corporate Governance Committee and our Board of Directors to determine that the person should serve as a director, given our business and structure. Name Age Position(s) with Traws Pharma, Inc. Served as Director From Werner Cautreels, Ph.D. 71 Director and Chief Executive Officer 2024 Iain Dukes, D. Phil. 65 Executive Chairman 2024 Nikolay Savchuk, Ph.D. 55 Director and Chief Operating Officer 2024 Trafford Clarke, Ph.D. 66 Director 2022 James J. Marino 74 Director 2015 M. Teresa Shoemaker 63 Director 2020 Jack E. Stover 71 Director 2016 Werner Cautreels, Ph.D. Dr. Cautreels has served as a director and CEO of the Company since April 1, 2024. Dr. Werner Cautreels is a highly accomplished biopharmaceutical executive with a core emphasis in research and development in various therapeutic areas, who brings a deep understanding of clinical and regulatory strategy. During his 40-year plus career, his work has touched on cardiovascular, autoimmune, oncology, rare disease, and vaccines. Dr. Cautreels was President and CEO of Selecta Biosciences from July 2010 until 2018. Prior to Selecta Biosciences, Dr. Cautreels served as Global CEO of Solvay Pharmaceuticals until it was acquired by Abbott Laboratories in 2010. Prior to joining Solvay, he worked at Sanofi, Sterling Winthrop and Nycomed-Amersham in a variety of research and development management positions in Europe and the United States. Dr. Cautreels was also a Director of

View Full Filing

View this 10-K/A filing on SEC EDGAR